BRIEF-AstraZeneca Says Nirsevimab Phase III Trial Met Primary Endpoint
- Country:
- Russian Federation
AstraZeneca PLC: * ASTRAZENECA PLC - NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT
* ASTRAZENECA PLC - NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINT * ASTRAZENECA - FIRST POTENTIAL PASSIVE IMMUNISATION TO SHOW PROTECTION AGAINST RSV IN GENERAL INFANT POPULATION
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
- READ MORE ON:
- AstraZeneca PLC
Advertisement